An oncologist observed that some ITP patients treated with rilzabrutinib or yanalumab experienced an unexpected side benefit: improvement in their seasonal allergy symptoms. This suggests these autoimmune-targeted therapies may have broader effects on immune dysregulation beyond just ITP.

ITP caused by immune checkpoint inhibitors (ICIs) is rare (0.25% incidence) but generally has a good prognosis. Most patients respond to standard first-line ITP therapies, and approximately 70% of those re-challenged with the ICI can continue treatment without a recurrence of ITP.

The VEHIT2 trial protocol, combining yanalumab and eltrombopag shortly after steroid failure, represents a paradigm shift. It moves beyond sequential single-agent therapy to explore if early, potent intervention can fundamentally reduce the long-term severity and chronic nature of ITP.

Contrary to common assumptions, standard initial steroid therapy is ineffective for the vast majority of adult ITP patients. Approximately 80% progress to chronic disease, highlighting the urgent need for more effective first- and second-line therapies to alter the disease course.

The treatment paradigm for ITP is shifting towards early combination therapy. Recent clinical trials are investigating augmented first- and second-line regimens, such as combining dexamethasone with rituximab or romiplostim, to achieve more durable, treatment-free responses than monotherapy.

While used for ITP, rituximab (a CD20 antibody) actually increases levels of BAF, a cytokine that promotes B-cell growth. This is counterproductive. In contrast, newer agents like unalumab block the BAF receptor, offering a more direct and potentially superior mechanism of action.

The primary goal after managing immune checkpoint inhibitor (ICI)-induced ITP is resuming cancer therapy. Data shows most patients do not experience a relapse of ITP upon re-challenge with the ICI, allowing them to continue their effective cancer treatment.

In the VahIT-three trial, heavily pre-treated ITP patients achieved a 44% response rate with just four infusions of unalumab. This offers a significant advantage over chronic daily therapies, providing a short treatment course with the potential for durable response in a difficult-to-treat population.

Historical data showing high cure rates for splenectomy in ITP is outdated. Recent data indicates that if a patient has already failed both a TPORA and rituximab, the chance of a successful splenectomy is less than 50%, repositioning it as a later-line salvage option.